Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy.
Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy.
Int J Mol Sci. 2020 May 10;21(9):3377. doi: 10.3390/ijms21093377.
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.
当前的大流行冠状病毒 SARS-CoV-2 因其高度传染性、大量需要重症监护治疗的患者以及高死亡率而成为全球卫生紧急情况。在没有特定抗病毒药物、被动预防或疫苗的情况下，这些患者的治疗目的是防止强烈的病毒诱导的炎症刺激导致急性呼吸窘迫综合征 (ARDS)，后者预后严重。在这里，我们回顾了作用机制和使用免疫策略的基本原理，这些策略包括从传统化学合成药物、抗细胞因子抗体、静脉用人免疫球蛋白到疫苗等。
